Role of racemization in optically active drugs development

462 ALI ET AL.
34. Skalova L, Kral R, Szotakova B, Babu YN, Pichard-Garcia L, Wsol V.
Chiral aspects of metabolism of anti-inflammatory drug flobufen in
human hepatocytes. Chirality 2003;15:433–440.
35. Mason JP, Hutt AJ. Stereochemical aspect of drug metabolism. In:
Aboul-Enein HY, Wainer IW, editors. The impact of stereochemistry
on drug development and use. New York: Wiley; 1997. p 45–123.
36. Zheng H, Jiang C, Chiu MH, Covey JM, Chan KK. Chiral pharmacokinetics
and inversion of a new quinoxaline topoisomerase II b position
in the rat. Drug Metab Dispos 2002;30:344–348.
37. Hasegawa H, Matsukawa T, Shinohara Y, Hashimoto T. Assessment
of the metabolic chiral inversion of D-leucine in rat by gas chromatography-mass
spectrometry combined a stable isotop dilution analysis.
Drug Metab Dispos 2000;28:920–924.
38. Wsol V, Kral R, Skalova L, Szotakova B, Trejtnar F, Flieger M. Stereospecificity
and stereoselectivity of flobufen metabolic profile in male
rats in vitro and in vivo: phase I of biotransformation. Chirality
2001;13:754–759.
39. Yang SK, Bao Z, Shou M. Stereoselective nucleophilic substitution of
oxazepam and racemization in acidic methanol and ethanol. Chirality
1996;8:214S–223S.
40. Yang SK. Racemization and stereoselective alcoholysis of temazepam.
Chirality 1999;11:179–186.
41. Yang SK. Substitution and racemization of 3-hydroxy- and 3-alkoxy-
1,4-benzodiazepines in acidic aqueous solutions. Chirality 1995;7:
365–375.
42. Yang SK, Bao Z. Base-catalysed racemization of 3-O-acyloxazepam.
Chirality 1994;6:321–328.
43. Yang SK. Acid-catalysed stereoselective heteronucleophilic substitution
and racemization of 3-O-methyloxazepam and 3-O-ethyloxazepam.
Chirality 1994;6:175–184.
44. Yang SK, Lu XL. Acid-catalysed nucleophilic substitution and racemization
of 3-methoxy-N-desmethyldiazepam enantiomers in methanol.
Chirality 1993;5:91–96.
45. Yang SK, Lu XL. Racemization kinetics of enantiomeric oxazepams and
stereoselective hydrolysis of enantiomeric oxazepam 3-acetate in rat
liver microsomes and brain homogenate. J Pharm Sci 1989;78:789–795.
46. Yang SK, Lu XL. Resolution and stability of oxazepam enantiomers.
Chirality 1992;4:443–446.
47. Yang SK. Mechanism of racemization of 3-hydroxy-1,4-benzodiazepines
in alcoholic solvents. Enantiomer 1998;3:485–490.
48. Sulla TV. Racemizzazione in ambiente acido dei cloruri del tipo
RCH(R’)COCl. Ric Sci 1962;32:181–183.
49. Ferorelli S, Loiodice F, Longo A, Molfetta A, Tortorella V, Amoroso
R. Different behavior toward racemization in basic media from chiral
analogs of clofibric acid, the active metabolite of the antilipidemic
drug clofibrate. Chirality 2000;12:697–704.
50. Gualtieri F, Bottalico C, Calandrella A, Dei S, Giovannoni MP, Mealli
S, Romanelli MN, Scapecchi S, Teodori E, Galeotti N, Ghelardini C,
Giotti A, Bartolini A. Presynaptic cholinergic modulators as potent
cognition enhancers and analgesic drugs. 2. 2-Phenoxy-, 2-(Phenylthio)-,
and 2-(Phenylamino)alkanoic acid esters. J Med Chem
1994;37:1712–1719.
51. Mey B, Paulus H, Lamparter E, Blaschke G. Kinetics of racemization
of (þ)- and ( )-diethylpropion: studies in aqueous solution, with and
without the addition of cyclodextrins, in organic solvents and in
human plasma. Chirality 1998;10:307–315.
52. Tumambac GE, Francis CJ, Wolf C. Configurational stability of 2-benzoylcyclohexanone:
unexpected solvent effects on the rate of racemization.
Chirality 2005;17:171–176.
53. Fernandez C, Gimenez F, Mayrargue J, Thuillier A, Farinotti R. Degradation
and racemization of zopiclone enantiomers in plasma and
partially aqueous solutions. Chirality 1995;7:267–271.
54. Lamparter E, Blaschke G, Schluter J. Racemization of chlorthalidone
in the presence of liposomes. Chirality 1993;5:370–374.
55. Murakami K, Ohashi M, Matsunaga A, Yamamoto I, Nohira H. Asymmetric
transformation of a racemic-a(phthalimidooxy)arylacetic ester
by a combination of preferential crystallization and simultaneous racemization.
Chirality 1993;5:41–48.
Chirality DOI 10.1002/chir
56. de Gaitani CM, Martinez AS, Bonato PS. Degradation and configurational
changes of thioridazine 2-sulfoxide. J Pharm Biomed Anal
2004;36:601–607.
57. Eap CB, Koeb L, Baumann P. Artifacts in the analysis of Thioridazine
and other neuroleptics. J Pharm Biomed Anal 1993;11:451–457.
58. Knoche B, Blaschke G. Racemization of thalidomide in vitro. Presented
at the 4th International symposium on chiral discrimination,
September 19–22, 1993, Montreal, Canada. Abstract 144.
59. Schmahl HJ, Heger W, Nau H. The enantiomers of the teratogenic
thalidomide analogue EM 12. Toxicol Lett 1989;45:23–33.
60. Eger K, Jalalian M, Verspohl EJ, Lüpke NP. Synthesis, central nervous
system activity and teratogenicity of a homothalidomide. Arzneim-Forsch
(Drug Res) 1990;40:1073–1075.
61. Nunes MA, Brochmann-Hanssen E. Hydrolysis and epimerization
kinetics of pilocarpine in aqueous solution. J Pharm Sci 1974;63:716–721.
62. Pepper C, Smith HJ, Barrell KJ, Nicholls PJ, Hewlins MJE. Racemization
of drug enantiomers by benzylic proton abstraction at physiological
pH. Chirality 1994;6:400–404.
63. Sanins SM, Adams WJ, Kaiser DG, Halstead GW, Hosley J, Barnes
H, Baillie TA. Mechanistic studies on the metabolic chiral inversion
of R-ibuprofen in the rat. Drug Metab Dispos 1991;19:405–410.
64. Adams SS, Bresloff P, Mason CG. Pharmacological differences
between the optical isomers of ibuprofen: evidence for metabolic
inversion of the ( )-isomer. J Pharm Pharmacol 1976;28:256–257.
65. Kaiser DG, Van-Giessen GJ, Reischer RJ, Wechter WJ. Isomeric
inversion of ibuprofen (R)-enantiomer in humans. J Pharm Sci 1976;
65:269–273.
66. Lee E, Williams KM, Day R, Graham G, Champion D. Stereoselective
disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol
1985;19:669–674.
67. Chen CS, Shieh WR, Lu PH, Harriman S, Chen CY. Metabolic stereoisomeric
inversion of ibuprofen in mammals. Biochim Biophys Acta
1991;1078:411–417.
68. Aboul-Enein HY, Wainer IW, editors. The impact of stereochemistry
on drug development and use. New York: Wiley; 1997.
69. Wechter WJ, Loughhead DG, Reischer RJ, VanGiessen GJ, Kaiser
DG. Enzymic inversion at saturated carbon. Nature and mechanism
of the inversion of R ( ) p-isobutyl hydratropic acid. Biochem
Biophys Res Commun 1974;61:833–837.
70. Reichel C, Brugger R, Bang H, Geisslinger G, Brune K. Molecular
cloning and expression of a 2-arylpropionyl-coenzyme A epimerase: a
key enzyme in the inversion metabolism of ibuprofen. Mol Pharmacol
1997;51:576–582.
71. Williams KM, Day RO. Stereoselective disposition-basis for variability
in response to NSAIDs. Agents Actions 1985;17:119–126.
72. Tracy TS, Hall SD. Metabolic inversion of (R)-ibuprofen. Epimerization
and hydrolysis of ibuprofenyl-coenzyme A. Drug Metab Dispos
1992;20:322–327.
73. Sanins SM, Adams WJ, Kaiser DG, Halstead GW, Baillie TA. Studies
on the metabolism and chiral inversion of ibuprofen in isolated rat
hepatocytes. Drug Metab Dispos 1990;18:527–533.
74. Knights KM, Addinall YF, Roberts BJ. Enhanced chiral inversion of
R-ibuprofen in liver from rats treated with clofibric acid. Biochem
Pharmacol 1991;41:1775–1777.
75. Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30
years. Clin Pharmacokinet 1998;34:101–154.
76. Tan SC, Patel BK, Jackson SHD, Swift CG, Hutt AJ. Ibuprofen stereochemistry:
double-the-trouble? Enantiomer 1999;4:195–203.
77. Evans AM. Comparative pharmacology of S(þ)-ibuprofen and (RS)ibuprofen.
Clin Rheumatol 2001;1:9–14.
78. Kemal C, Casida JE. Coenzyme A esters of 2-aryloxyphenoxypropionate
herbicides and 2-arylpropionate anti-inflammatory drugs are
potent and stereoselective inhibitors of rat liver acetyl-CoA carboxylase.
Life Sci 1992;50:533–540.
79. Sallustio BC, Meffin PJ, Knights KM. The stereospecific in corporation
of fenoprofen in to rat hepatocytes and adipocyte triacylglycerols.
Biochem Pharmacol 1988;37:1919–1923.